BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)

Investor Deep Dive — Prepared by Ada Cockpit, March 2026

Executive Summary

$3.22B FY 2025 Revenue
+13% Revenue Growth YoY
$927M VOXZOGO Revenue
32-33% Non-GAAP Op. Margin
$828M Operating Cash Flow
$11.7B Market Cap
$60.88 Stock Price (Mar '26)
$94.00 Analyst Median Target

BioMarin Pharmaceutical is a global biotechnology leader focused exclusively on rare genetic diseases, with eight approved therapies serving patients in approximately 80 countries. FY 2025 revenue of $3.22 billion was driven by VOXZOGO ($927M, +26% YoY) and the Enzyme Therapies franchise (~$2B, +9% YoY). The company is executing a multi-pronged growth strategy: maximizing VOXZOGO globally, expanding into new skeletal dysplasia indications (CANOPY program), developing BMN 333 as a next-generation therapy, and integrating the transformative $4.8 billion Amicus Therapeutics acquisition (expected Q2 2026 close).

Key Thesis: Post-Amicus, BioMarin will be the largest pure-play rare disease company globally with 10 approved products, $4B+ in pro forma revenue, and a path to 40%+ non-GAAP operating margins. Analyst consensus implies ~54% upside from current levels.

FY 2025 Revenue Mix

VOXZOGO $927M (29%) Enzyme Therapies ~$2.0B (62%) Other $293M (9%)

Revenue Growth (2019-2025)

$0B $1B $2B $3B $3.5B 2019 2020 2021 2022 2023 2024 2025 $1.70B $1.86B $1.85B $2.10B $2.42B $2.85B $3.22B

Company Overview & History

BioMarin Pharmaceutical Inc. was founded in March 1997 by Christopher Starr, Ph.D., and Grant W. Denison Jr. in Novato, California, with a mission to develop enzyme replacement therapies for rare genetic diseases. The company secured early funding from Glyko Biomedical ($1.5M), acquired that firm in 1998, and went public on NASDAQ in 1999.

Over nearly three decades, BioMarin has built the broadest commercial portfolio in rare diseases, with eight approved therapies and a track record of first-to-market products in several ultra-rare indications.

YearMilestone
1997Founded in Novato, CA
1999IPO on NASDAQ (BMRN)
2003FDA approval: Aldurazyme (MPS I) - co-developed with Genzyme
2005FDA approval: Naglazyme (MPS VI) - first independently developed product
2007FDA approval: Kuvan (PKU) - first pharmacological PKU treatment
2014FDA approval: Vimizim (MPS IVA / Morquio A syndrome)
2017FDA approval: Brineura (CLN2 / Batten disease)
2018FDA approval: Palynziq (PKU)
2021FDA approval: VOXZOGO (achondroplasia)
2023FDA approval: ROCTAVIAN (hemophilia A gene therapy); Alexander Hardy becomes CEO
2025Acquired Inozyme Pharma ($270M); agreed to acquire Amicus Therapeutics ($4.8B)

Headquarters: San Rafael, California. Manufacturing facilities in Novato, CA and Shanbally, Cork, Ireland. Commercial operations in ~80 countries.

Corporate Governance & Leadership

Executive Leadership

Alexander Hardy became President and CEO on December 1, 2023, succeeding long-time CEO Jean-Jacques Bienaime. Hardy (age 57) previously served as CEO of Genentech (Roche) and holds an MBA from Michigan Ross ('92). Total compensation: ~$14.85M annually.

ExecutiveTitleTenureCompensation
Alexander HardyPresident & CEO~2.3 years$14.85M
Brian R. MuellerEVP & CFO~6.2 years$5.50M
Cristin HubbardEVP & Chief Commercial Officer~1.8 years$6.93M
G. Eric DavisEVP & Chief Legal Officer~22 years$5.06M
Gregory R. FribergEVP & Chief R&D Officer——
C. Greg GuyerEVP & Chief Technical Officer——
James SabryEVP & Chief Business Officer——
Arpit DaveEVP & Chief Digital/Info Officer——
Marni KottleEVP & Chief Corporate Affairs Officer——
Amy WiremanEVP & Chief People Officer——

Board of Directors (11 Members)

DirectorBackgroundAppointed
Richard A. Meier (Chair)Board ChairPre-2024
Alexander HardyPresident & CEODec 2023
Barbara W. BodemDirectorPre-2024
Athena CountouriotisDirectorPre-2024
Elizabeth McKee AndersonDirectorPre-2024
Willard H. DereDirectorPre-2024
Mark J. EnyedyDirectorPre-2024
Maykin HoDirectorPre-2024
Robert J. HombachDirectorPre-2024
Timothy P. WalbertFormer CEO, Horizon TherapeuticsFeb 2025
Ian T. ClarkFormer CEO, GenentechAug 2025

Ownership Structure

CategoryShares% Outstanding
Institutional Investors183.27M95.57%
Insiders2.72M1.42%
Retail / Other~5.79M~3.01%
Total Outstanding191.78M100%

Top institutional holders: BlackRock (largest), Vanguard, Dodge & Cox, Primecap Management, Norges Bank, State Street, Viking Global Investors (3.14%), Geode Capital (1.91%). Total institutional owners: 942.

Commercial Portfolio

5.1 VOXZOGO (vosoritide) Flagship

Indication: Achondroplasia (children 4 months+ with open growth plates)
Mechanism: C-type natriuretic peptide (CNP) analog promoting endochondral bone growth
Administration: Daily subcutaneous injection
Markets: 55 countries; ~73% of revenue from outside the U.S.

YearRevenueYoY Growth
2022~$169MLaunch ramp
2023$470M+178%
2024$735M+56%
2025$927M+26%

5.2 Enzyme Therapies (~$2.0B, +9% YoY in 2025)

ProductIndicationFDA Approved2025 GrowthAdmin
Palynziq (pegvaliase)PKU (adults)2018+22% YoYDaily SC injection
Vimizim (elosulfase alfa)MPS IVA (Morquio A)2014+7% YoYWeekly IV
Naglazyme (galsulfase)MPS VI2005StableWeekly IV
Brineura (cerliponase alfa)CLN2 / Batten disease2017StableBiweekly ICV
Aldurazyme (laronidase)MPS I2003Normalized after 2024 timingWeekly IV
Kuvan (sapropterin)PKU2007Declining (generics)Daily oral

5.3 ROCTAVIAN (valoctocogene roxaparvovec) Divesting

Indication: Severe hemophilia A (gene therapy, one-time treatment)
Price: ~$2.9 million per treatment
2024 Revenue: $26 million
Status: Being divested. Commercial focus narrowed to U.S., Italy, Germany. BioMarin announced plans to out-license in Q3 2025 after persistently weak uptake. Roctavian-related charges contributed to 18% net income decline in FY 2025.

Research Pipeline

ProgramIndicationMechanismPhaseKey Milestone
BMN 333AchondroplasiaLong-acting CNPPhase 1PK data >3x target; pivotal study 2026; target approval ~2030
VOXZOGO (CANOPY HCH-3)HypochondroplasiaCNP analogPhase 3Enrollment complete Apr 2025; topline data 2026
VOXZOGO CANOPYIdiopathic short stature, Noonan, Turner, SHOXCNP analogPhase 2Multiple studies recruiting
PALYNZIQ adolescentPKU (ages 12-17)PEGylated PALPhase 3Results and regulatory submission expected
INZ-701 (Inozyme)ENPP1 DeficiencyEnzyme replacementPhase 3Potential first-in-disease therapy
VOXZOGO full approvalAchondroplasiaCNP analogsNDAU.S. submission expected Q2 2026
BMN 333 Spotlight: Phase 1 data in healthy volunteers showed AUC exposure for free CNP exceeding targets by >3x, and a 2.1x ratio versus competitor long-acting CNP agents. FDA agreement reached on clinical plan. This is BioMarin's key lifecycle management asset to defend against Ascendis Pharma's TransCon CNP.

Financial Performance

Revenue Trajectory

YearRevenueYoY GrowthKey Driver
2019$1.70B+14.3%Enzyme therapy growth
2020$1.86B+9.2%Resilient through COVID-19
2021$1.85B-0.8%Slight decline; VOXZOGO launch
2022$2.10B+13.5%VOXZOGO ramp-up
2023$2.42B+15.4%VOXZOGO $470M (+178%)
2024$2.85B+17.8%VOXZOGO $735M (+56%)
2025$3.22B+13.0%VOXZOGO $927M (+26%)

Quarterly Revenue (2025)

QuarterRevenueYoY GrowthHighlight
Q1 2025$745M+15%VOXZOGO +40%
Q2 2025$825M+16%Raised FY guidance
Q3 2025$776M+4%Order timing headwinds
Q4 2025$875M+17%VOXZOGO +31%; gov't orders

Profitability & Cash Flow

Metric202420252026 Guidance
Non-GAAP Operating Margin~28%32-33%~40% (excl. Amicus)
GAAP Net Income~$425M (est.)$349M—
Non-GAAP Diluted EPS—$4.20-4.40Improving
Operating Cash Flow$573M$828M>$1.25B by 2027
Cash & Investments~$1.7B~$2.0B—

Geographic Footprint

BioMarin operates in ~80 countries. Revenue is globally diversified with approximately 65-70% from outside the United States.

RegionEst. % of RevenueKey Markets
United States~30-35%Primary market for all products
Europe~30-35%Germany, Italy, UK, France, Spain, Nordics
Rest of World~30-35%Latin America, Middle East, Asia-Pacific, Japan

VOXZOGO: ~73% OUS revenue in 2025. Latin America was a notable growth driver in Q4 2025 with large government orders.

Competitive Landscape

Achondroplasia (VOXZOGO's Market)

CompanyProductMechanismPhaseEst. Approval
BioMarinVOXZOGODaily SC CNPApproved2021
Ascendis PharmaTransCon CNPWeekly SC CNP prodrugPhase 3~2029-2030
BridgeBioInfigratinibDaily oral FGFR3 inhibitorPhase 3~2029-2030
RibomicRBM-007Anti-FGF2 aptamerEarly>2030
BioMarinBMN 333Long-acting CNPPhase 1~2030
Competitive Risk: Ascendis Pharma's TransCon CNP showed lower injection site reactions and hypotension rates vs. VOXZOGO. When results were announced, BMRN stock fell 17%. BioMarin has filed patent litigation against Ascendis at the EU Unified Patent Court (Jan 2025).

Broader Rare Disease Competition

CompetitorOverlap Area
Sanofi / GenzymeLysosomal storage disorders (will overlap post-Amicus in Fabry/Pompe)
UltragenyxUltra-rare disorders, skeletal dysplasias
PTC TherapeuticsPKU (Sephience competes with Kuvan/Palynziq)
Alexion / AstraZenecaLarge rare disease competitor
Sarepta, AlnylamRare disease space broadly

Strategic Transactions

Amicus Therapeutics Acquisition ($4.8 Billion) Pending

DetailValue
AnnouncedDecember 19, 2025
Price$14.50/share, all-cash (33% premium)
Expected CloseQ2 2026
Shareholder ApprovalSecured March 2026 (74.79% of eligible shares voted in favor)
Key AssetsGalafold (Fabry; $458M rev in 2024, +18% YoY; US exclusivity to 2037)
Pombiliti + Opfolda (Pompe; $599M trailing 4Q rev)
DMX-200 (FSGS, Phase 3)
AccretionExpected accretive to non-GAAP diluted EPS within 12 months

Inozyme Pharma Acquisition ($270 Million)

Completed July 1, 2025. Added INZ-701 (Phase 3 ERT for ENPP1 Deficiency). First M&A under Chief Business Officer James Sabry.

Risk Factors

Key Risk Summary
  1. VOXZOGO competitive erosion: Ascendis TransCon CNP and BridgeBio infigratinib could take share from ~2029-2030
  2. Revenue concentration: VOXZOGO = 29% of FY2025 revenue; single-product growth dependence
  3. Amicus integration risk: $4.8B deal adds leverage and execution complexity
  4. ROCTAVIAN write-down: ~$2.9B cumulative R&D investment with minimal return; $26M in 2024 revenue
  5. Kuvan patent expiration: Key patents expired 2024-2026; generic competition accelerating
  6. BMN 333 development risk: Phase 1 only; 4+ years to potential approval
  7. CANOPY execution risk: Phase 3 failure in hypochondroplasia would limit TAM expansion
  8. International FX exposure: ~65-70% OUS revenue exposed to currency fluctuations
  9. Pricing pressure: Increasing payer scrutiny on rare disease therapy pricing globally
  10. Valuation: 34x trailing P/E; stock down 13.6% over 12 months despite revenue growth

Outlook & 2026 Guidance

2026 Financial Guidance (Excluding Amicus)

Metric2026 Guidancevs. 2025
Total Revenue$3.325-3.425B+3-6%
Enzyme Therapies$2.225-2.275BHigh single-digit growth
Non-GAAP Operating Margin~40%+700-800 bps

Analyst consensus: 44 analysts; median 12-month target $94.00 (range $55-$126); consensus rating: Strong Buy. Implies ~54% upside.

Key 2026 Catalysts

TimingCatalyst
Q2 2026Amicus acquisition close; adds Galafold + Pombiliti + Opfolda revenue
H1 2026CANOPY HCH-3 Phase 3 topline data (hypochondroplasia)
Q2 2026VOXZOGO sNDA for full approval in achondroplasia
2026BMN 333 detailed Phase 1 data; pivotal study initiation
H2 2026Pombiliti + Opfolda adolescent label expansion
2026PALYNZIQ Phase 3 adolescent results
2026Non-GAAP operating margin expansion to ~40%

Investment Thesis

Bull Case:
Bear Case:

References

  1. Portersfiveforce.com, "Brief History of BioMarin." Link
  2. DCFModeling.com, "BioMarin History, Mission, Ownership." Link
  3. PESTEL Analysis, "Brief History of BioMarin." Link
  4. Wikipedia, "BioMarin Pharmaceutical." Link
  5. BioMarin Pharmaceutical, "About Us." Link
  6. BioPharma Dive, "BioMarin CEO Succession," 2023. Link
  7. Michigan Ross, "Alexander Hardy, MBA '92." Link
  8. SimplyWall St, "BioMarin Management." Link
  9. BioMarin, "Board of Directors." Link
  10. BioMarin, "Leadership." Link
  11. Fintel, "BioMarin Institutional Ownership." Link
  12. GuruFocus, "BMRN Ownership." Link
  13. BioMarin Press Release, "Q4 and FY 2024 Results," Feb 2025. Link
  14. BioMarin Press Release, "Q4 and FY 2025 Results," Feb 2026 (PRNewswire). Link
  15. BioMarin Press Release, "Q4 and FY 2025 Results," Feb 2026. Link
  16. BioMarin Press Release, "Q1 2025 Results," May 2025. Link
  17. BioMarin, "Products and Pipeline." Link
  18. BioMarin Press Release, "FDA Approves Brineura," Apr 2017. Link
  19. BioMarin Investor Release, "Brineura Under 3 Approval," Jul 2024. Link
  20. BioMarin Press Release, "Q3 2025 Results," Oct 2025. Link
  21. BioMarin Press Release, "Paragraph IV Notice for Kuvan." Link
  22. PESTEL Analysis, "BioMarin Competitors." Link
  23. StockAnalysis, "BMRN Revenue History." Link
  24. Investing.com, "BioMarin Q4 2025 Earnings Transcript," Feb 2026. Link
  25. BioSpace, "BioMarin Abandons Roctavian," 2025. Link
  26. BioMarin Press Release, "Q3 2025 Corporate Update," Oct 2025. Link
  27. Fierce Pharma, "BioMarin Long-Acting Voxzogo Data," 2025. Link
  28. BioMarin Press Release, "Q2 2025 Results," Jul 2025. Link
  29. BioMarin, "VOXZOGO CANOPY Data at Endocrinology Meetings," 2025. Link
  30. BioMarin Investor Release, "Inozyme Acquisition," May 2025. Link
  31. Investing.com, "BioMarin Q4 2025 Revenue Growth," Feb 2026. Link
  32. PRNewswire, "BioMarin Q2 2025 Results," Jul 2025. Link
  33. Delve Insight, "Achondroplasia Treatment Landscape." Link
  34. BioSpace, "Contenders in Achondroplasia," 2024. Link
  35. BioMarin Press Release, "Ascendis UPC Lawsuit," Jan 2025. Link
  36. BioMarin Press Release, "Amicus Acquisition," Dec 2025. Link
  37. Pharmaceutical Technology, "BioMarin Acquires Amicus $4.8B," Dec 2025. Link
  38. Investing.com, "Amicus Shareholders Approve Acquisition," Mar 2026. Link
  39. TickerNerd, "BMRN Stock Forecast." Link
  40. MarketBeat, "BMRN Forecast." Link
  41. BioMarin Investor Relations, "Stock Info." Link
  42. BioMarin Investor Relations, "Quarterly Results." Link
  43. StockAnalysis, "BMRN Employees." Link
  44. BioMarin JPM 2026 Presentation, Jan 2026. Link
  45. BioMarin, "Research Pipeline." Link
  46. Fierce Pharma, "JPM24: BioMarin CEO Hardy on Voxzogo," Jan 2024. Link
  47. Porter's Five Forces, "BioMarin Competitors." Link
  48. CompaniesMarketCap, "BioMarin Revenue." Link
  49. BioMarin EU, "About Us." Link
  50. Fintool, "BMRN People." Link

BioMarin Deep Dive - Ada Cockpit - March 2026

Disclaimer: This report is for informational purposes only and does not constitute investment advice. Data sourced from publicly available information as of March 2026. Financial figures should be verified against BioMarin's official SEC filings. Past performance is not indicative of future results.